secwatch.observer — SEC 8-K summary
======================================

Issuer:     Braveheart Bio, Inc. (BRVE)
CIK:        0002131524
Form:       8-K
Filed at:   2026-09-08T20:06:55+00:00
Accession:  0001628280-26-060904
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Braveheart Bio Q2 2026 net loss $18.6M; cash $527.3M after IPO; Phase 3 trials advancing
--------------------------------------------------------------------------------

- Cash $122.8M at 6/30/26; $527.3M pro forma after Aug IPO net ~$404.5M; runway into 2029.
- Net loss $15.0M; attributed to common stockholders $18.6M ($2.51/sh) vs $0.4M ($0.14/sh) in Q2 2025.
- LIONHEART-HCM Phase 3 for oHCM initiated; first patient dosing expected 2026, interim results 2H 2027.
- NOBLEHEART-HCM Phase 3 in nHCM expected to start 1H 2027 after Q2 Phase 2 data presented at HFA-ESC 2026.
- R&D expense $11.1M (vs $0.0M), G&A $4.8M (vs <$0.1M) on advancement and public-company prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/0001628280-26-060904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/bhb-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-060904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer